https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

EHA 2025: Golcadomide Shows Deep Responses in High-Risk Follicular Lymphoma

EHA 2025: Golcadomide Shows Deep Responses in High-Risk Follicular Lymphoma

Julio C. Chavez, MD, MS, discusses the distinct pharmacologic profile, clinical activity, and outpatient potential of golcadomide plus rituximab in relapsed/refractory follicular lymphoma, highlighting its selective cereblon modulation, fixed-duration dosing, and promising efficacy in heavily pretreated patients.

administrator

Related Articles